BRAINSTORM CELL THERAPEUTICS INC Form 3 July 12, 2007 UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 3 Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person <u>*</u> Lebovits Chaim			2. Date of Event RequiringStatement(Month/Day/Year)	3. Issuer Name and Ticker or Trading Symbol BRAINSTORM CELL THERAPEUTICS INC [BCLI]				
(Last) (First) (Middle) C/O BRAINSTORM CELL THERAPEUTICS INC., 110 EAST 59TH STREET (Street)		07/02/2007	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer Other (give title below) (specify below) President		Owner	 5. If Amendment, Date Original Filed(Month/Day/Year) 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting 		
NEW YORK, NY 10019						Person Form filed by More than One Reporting Person		
(City)	(State)	(Zip)	Table I - N	Non-Derivative Securities Beneficially Owned				
1.Title of Secur (Instr. 4)	ity		2. Amount o Beneficially (Instr. 4)		3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nat Owne (Instr.	*	
Reminder: Repo owned directly o	or indirectly. Person inform require	ns who resplation conta ation conta	ch class of securities benefic bond to the collection of ined in this form are not nd unless the form displ //B control number.		EC 1473 (7-02))		
Т	able II - Deri	ivative Secur	ities Beneficially Owned (e	.g., puts, calls,	warrants, opt	ions, c	onvertible securities)	

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security		4. Conversion or Exercise	5. Ownership Form of Derivative	6. Nature of Indirect Beneficial Ownership (Instr. 5)
			(Instr. 4)	•) Price of			
	Date Exercisable	Expiration Date	Title	Amount or Number of	Derivative Security	Security: Direct (D)	

OMB APPROVAL

Estimated average burden hours per

3235-0104

January 31,

2005

0.5

OMB

Number:

Expires:

response...

Shares	or Indirect
	(I)
	(Instr. 5)

Reporting Owners

Reporting Owner Name / Address	Relationships					
reporting of the Function and		10% Owner	Officer	Other		
Lebovits Chaim C/O BRAINSTORM CELL THERAPEUTICS INC. 110 EAST 59TH STREET NEW YORK, NY 10019	Â	Â	President	Â		
Signatures						
/s/ Thomas B. Rosedale (Pursuant to Power of Attorney)		07/12/2007				
**Signature of Reporting Person		Date				
Explanation of Responses:						

No securities are beneficially owned

- * If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.